Crescendo ACR Presentations Save

Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that six studies on Vectra® DA will be featured at the American College of Rheumatology (ACR) meeting being held Nov. 3-8, 2017 in San Diego, Calif.  Vectra DA has been shown to be the best predictor of the risk of radiographic progression, and the data from six studies had demonstrated that a high Vectra DA score was associated with a high risk of radiographic progression.

"Our presentations at this year's ACR reinforce our commitment to improving care for people living with rheumatoid arthritis," said Elena Hitraya, M.D., Ph.D., chief medical officer, Crescendo Bioscience.  "The new data add to a robust body of scientific knowledge supporting Vectra DA, which has been shown in multiple studies to be the best predictor of the risk of joint damage in patients with RA."

Please visit Crescendo Biosciences at Booth #712 for information about Vectra DA.  Abstracts are available online at: https://www.rheumatology.org/Annual-Meeting/Abstracts.  Below is a list of the highlighted Crescendo Bioscience presentations at ACR (#ACR17):

Podium Presentations

• Title: Effect of age and body mass index (BMI) on multi-biomarker disease activity (MBDA) score in patients with rheumatoid arthritis. Presenter: Kerri Ford. Date: Monday, Nov. 6, 2017: 4:30-6:00 p.m. PT. Abstract: 1900.
• Title: Validation of biomarkers to predict flare in polyarticular JIA upon stopping anti-TNF therapy. Presenter: Daniel Lovell. Date: Tuesday, Nov. 7, 2017: 4:30-6:00 p.m. PT. Abstract: 2858.

Poster Presentations

• Title: Impact of the multi-biomarker disease activity score results on whether rheumatologists changed biologic therapy for RA patients. Presenter: Jeffrey Curtis. Date: Sunday, Nov. 5, 2017: 9:00-11:00 a.m. PT. Abstract: 129.
• Title: High multi-biomarker disease activity score is associated with high risk of radiographic progression in six studies. Presenter: Jeffrey Curtis. Date: Sunday, Nov. 5, 2017: 9:00-11:00 a.m. PT. Abstract: 438. 
• Title: Prediction of cardiovascular events in rheumatoid arthritis patients using a multi-biomarker of disease activity. Presenter: Fenglong Xie. Date: Sunday, Nov. 5, 2017: 9:00-11:00 a.m. PT. Abstract: 138.
• Title: Development of an adjusted multi-biomarker disease activity score for rheumatoid arthritis that accounts for age, sex, and adiposity, with evaluation of ability to predict risk for radiographic damage. Presenter: Jeffrey Curtis. Date: Monday, Nov. 6, 2017: 9:00-11:00 a.m. PT. Abstract: 1371.